Get started
Author

Elizabeth M. Corley

Observed names: E.M., Corley, Elizabeth Corley, Elizabeth M Corley
ORCID: 0000-0002-0077-9750
Observed ORCID: 0000-0002-0077-9750
OpenAlex ID: A5034809791
Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia
2023 · Moaath K. Mustafa Ali, Matthew T. Williams, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 27
PDF
Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
2022 · Moaath K. Mustafa Ali, Elizabeth M. Corley, et al. · Frontiers in Oncology · 18
Characterization and predictive risk scoring of long COVID in a south indian cohort after breakthrough COVID infection; a prospective single centre study
2023 · Pranav Nair, Chithira V Nair, et al. · BMC Infectious Diseases · 15
PDF
Immune thrombocytopenia in patients treated with immune checkpoint inhibitors
2025 · Rebecca K. Leaf, Jodi V. Mones, et al. · Blood · 13
Patient Frustration with Pelvic Organ Prolapse Education Met with Resilient Response
2021 · Elizabeth M. Corley, Pranaya Terse, et al. · Neurourology and Urodynamics · 8
Impact of IDH1 c.315C>T SNP on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
2022 · Elizabeth M. Corley, Moaath K. Mustafa Ali, et al. · Frontiers in Oncology · 5
Impact of FLT3-ITD Insertion Length on Outcomes in Acute Myeloid Leukemia: A Propensity Score-Adjusted Cohort Study
2022 · Elizabeth M. Corley, Moaath K. Mustafa Ali, et al. · Biology · 4
PDF
Chronic Enterovirus Meningitis with Acute Hepatitis in a Patient with Chronic Lymphocytic Leukemia Treated with Venetoclax/Obinutuzumab: A Case Report
2025 · Kaya L. Curtis, Elizabeth M. Corley, et al. · Case Reports in Oncology · 2
PDF
Expect the unexpected: fulminant myocardial cytotoxic Injury from Trabectedin
2024 · Annie J. Tsay, Mohan Satish, et al. · Cardio-Oncology · 2
PDF
Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study
2022 · Hanan Alharthy, Fahad Alkaabba, et al. · Blood · 2
Prognostication of the 2016-Who AML with Myelodysplasia-Related Changes Subclass and Mutations in MDS-Related Genes Using the 2022 European Leukemianet Risk Classification: A Retrospective Study
2022 · Fahad Alkaabba, Matthew Williams, et al. · Blood · 2
AML-1357: Outcomes in Acute Myeloid Leukemia With MECOM Rearrangement (MECOMr-AML) Treated With Hypomethylating Agent Plus Venetoclax
2025 · Leora Boussi, Elizabeth Corley, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Expect the Unexpected: Trabectedin-induced Myocardial Injury
2024 · Annie Tsay, Elizabeth M. Corley, et al. · Journal of the American College of Cardiology · 1
Immune thrombocytopenia in patients treated with immune checkpoint inhibitors
2025 · Rebecca Leaf, Jodi Mones, et al. · Blood
PDF
Characteristics and outcomes in Acute Myeloid Leukemia with Mecom rearrangement treated with hypomethylating agent plus venetoclax
2025 · Leora Boussi, Elizabeth Corley, et al. · Blood
PDF
POSTER: AML-1357 Outcomes in Acute Myeloid Leukemia With MECOM Rearrangement (MECOMr-AML) Treated With Hypomethylating Agent Plus Venetoclax
2025 · Leora Boussi, Elizabeth Corley, et al. · Clinical Lymphoma Myeloma & Leukemia
425. Characterization and predictive risk scoring of long COVID in a South Indian cohort after breakthrough COVID infection; a prospective single centre study
2023 · Merlin Moni, Pranav Nair, et al. · Open Forum Infectious Diseases
PDF
Works count: 18
Citation count: 100
H-index: 5
I10-index: 4
Year
Topic
Type